Facebook Inc. took a momentous action last week. And I don’t mean its announced intention to sell shares for $28 to $35 in an initial public offering later this month.

Senator Carl Levin says that Facebook is exploiting a tax loophole in order to avoid paying taxes to the government. But Facebook is a textbook case of win-win-win: the company's creators get rich, society gets the benefit of an innovative communications platform, and the U.S. Treasury gets billions in new revenues.

Facebook’s IPO will be good news for a whole host of reasons. In particular, users should be happy that the company will become a much more public-facing entity.

We got more tussle and a whole bunch of dumb questions in the Meet the Press/NBC/Facebook/Union Leader/Channel 7 debate (are these things improved by having more sponsors? No) this morning.

The future is on the way.  Leading-edge innovators, we are assured, have already moved on, and are earnestly focusing on the just the sort of problems - manufacturing, energy, transportation (and I'd add healthcare) - that urgently require imaginative solutions.

The nation is consumed with economic problems, yet a national security crisis can shift our priorities in a single moment. It's time to find out how the men and women who would be president will perform when that crisis hits.

Mark Zuckerberg probably never dreamed when he invented Facebook to connect college students that it would someday save a life.

Today, URL Pharma was acquired by Takeda for nearly $800M.  The story here in brief is that for hundreds of years, colchicine was used for the treatment of gout and other conditions; it was an effective drug but had to be used carefully. URL invested in the formulation development and clinical studies required for colchicine, and ultimately received FDA approval in 2009.